Suppliers and packagers for generic pharmaceutical drug: TIRBANIBULIN

TIRBANIBULIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189	NDA	Almirall, LLC	16110-391-05	5 PACKET in 1 CARTON (16110-391-05) / .25 g in 1 PACKET	2020-12-14
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189	NDA	Almirall, LLC	16110-391-55	5 PACKET in 1 CARTON (16110-391-55) / .35 g in 1 PACKET	2020-12-14

TIRBANIBULIN DRUG SUPPLIERS

Last updated: February 19, 2026

This report details the key suppliers involved in the manufacturing and supply chain of tirbanibulin, a topical microtubule inhibitor used for actinic keratosis. The analysis focuses on identified active pharmaceutical ingredient (API) manufacturers and significant contract manufacturing organizations (CMOs) that have played a role in tirbanibulin's development and commercialization. Understanding these suppliers is critical for assessing supply chain resilience, identifying potential bottlenecks, and evaluating competitive landscapes for tirbanibulin production.

WHO ARE THE PRIMARY ACTIVE PHARMACEUTICAL INGREDIENT (API) SUPPLIERS FOR TIRBANIBULIN?

The primary active pharmaceutical ingredient (API) for tirbanibulin is manufactured by specific entities with demonstrated capabilities in complex organic synthesis and adherence to stringent pharmaceutical quality standards. These API suppliers are foundational to the tirbanibulin supply chain.

• OncoImmune GmbH: This German-based company is identified as a key manufacturer of tirbanibulin API. OncoImmune has been involved in the development and supply of the API for the drug, which is marketed as Klisyri® in the United States and Europe. Their expertise lies in producing complex pharmaceutical intermediates and APIs, meeting regulatory requirements for drug substance manufacturing. The precise volume of API supplied by OncoImmune and their specific manufacturing capacity are proprietary, but their role is central to the drug's availability. [1]

• Contract Manufacturing Organizations (CMOs): Beyond direct API synthesis, CMOs are integral to ensuring consistent and scaled production. While specific details of all CMOs involved can be proprietary, they typically handle various stages of drug substance manufacturing, purification, and potentially formulation under contract. The selection of CMOs is based on their Good Manufacturing Practice (GMP) compliance, scalability, and track record with similar complex molecules.

WHAT CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) ARE INVOLVED IN TIRBANIBULIN'S FORMULATION AND MANUFACTURING?

The transformation of tirbanibulin API into the final finished drug product, Klisyri®, involves specialized CMOs. These organizations are responsible for the precise formulation of the topical ointment, packaging, and often secondary manufacturing processes.

• Almac Group: Almac Group, a global contract development and manufacturing organization (CDMO), has been involved in the clinical and commercial manufacturing of tirbanibulin. Their services encompass API handling, drug product manufacturing, and packaging. Almac's involvement signifies the need for specialized facilities capable of producing topical formulations under strict quality control. They provide integrated services that support the lifecycle of pharmaceutical products from early development through commercial supply. [2] The scale of their involvement and specific production sites are commercially sensitive.

• Specialized Topical Formulation Manufacturers: The development of a topical formulation like tirbanibulin requires CMOs with expertise in creating stable, effective, and patient-friendly ointment bases. These CMOs manage the blending of the API with excipients, ensuring uniformity and appropriate physical characteristics for topical application. The selection of these CMOs is driven by their ability to handle specific rheological properties, ensure API stability within the formulation, and meet packaging requirements for precise dosing.

HOW DOES THE SUPPLY CHAIN FOR TIRBANIBULIN COMPARE TO SIMILAR TOPICAL THERAPEUTICS?

The supply chain for tirbanibulin shares common characteristics with other topical therapeutics but also presents unique aspects related to the complexity of its API and the specialized nature of its manufacturing.

• API Complexity: Tirbanibulin is a synthetic small molecule, requiring multi-step organic synthesis. This complexity, compared to some simpler topical agents or biologics, necessitates highly specialized API manufacturers. The supply chain for such complex APIs is generally more concentrated, with fewer potential suppliers, increasing the criticality of maintaining relationships with existing manufacturers.

• Topical Formulation Expertise: The formulation of topical treatments, especially ointments and creams, demands specific expertise in blending, rheology, and stability testing. CMOs with established capabilities in dermatological formulations are sought after. This is a shared requirement across many topical drugs, meaning a competitive market exists for these specialized CMO services.

• Regulatory Scrutiny: All pharmaceutical supply chains are subject to rigorous regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For tirbanibulin, this includes GMP compliance at all manufacturing sites, from API synthesis to finished product packaging. The need for consistent quality and regulatory adherence is a universal factor in pharmaceutical manufacturing.

• Commercialization Scale: The scale of tirbanibulin manufacturing is directly tied to its market adoption for actinic keratosis. For blockbuster drugs with extensive global reach, supply chains must be robust and scalable to meet high demand. Tirbanibulin's commercial scale is dependent on prescription volumes and physician adoption. Manufacturers must have the capacity to scale up production without compromising quality.

WHAT ARE THE KEY CONSIDERATIONS FOR SUPPLY CHAIN RELIABILITY FOR TIRBANIBULIN?

Ensuring a consistent and uninterrupted supply of tirbanibulin requires addressing several key considerations within its manufacturing and distribution network.

• API Source Diversification: While OncoImmune GmbH is a primary API supplier, the long-term reliability of the supply chain would be enhanced by identifying and qualifying secondary API manufacturers. This diversification mitigates risks associated with single-source dependency, such as production disruptions, geopolitical instability, or supplier-specific quality issues. The qualification process for a new API supplier for a drug already on the market is resource-intensive, involving extensive validation and regulatory submissions.

• CMO Capacity and Redundancy: Similar to API manufacturing, securing adequate capacity at CMOs for formulation, filling, and packaging is crucial. Having redundant manufacturing sites or contractual agreements with multiple qualified CMOs can provide a buffer against unforeseen events, such as equipment failures, natural disasters, or labor shortages at a primary manufacturing facility.

• Inventory Management and Forecasting: Effective inventory management for both API and finished drug product is essential. Accurate demand forecasting, coupled with appropriate buffer stock levels, helps prevent stockouts. This requires close collaboration between the drug sponsor, API manufacturers, and CMOs to share market intelligence and production schedules.

• Logistics and Distribution Network: The efficient movement of raw materials, API, and finished products through the supply chain is paramount. This involves a well-established logistics network, including secure transportation, appropriate storage conditions (e.g., temperature control), and reliable distribution partners. Delays or disruptions in logistics can directly impact product availability.

• Quality Assurance and Regulatory Compliance: Maintaining the highest standards of quality assurance and continuous regulatory compliance across all supply chain partners is non-negotiable. Regular audits of manufacturing sites, robust quality management systems, and prompt adherence to evolving regulatory requirements are critical for preventing supply interruptions due to quality or compliance failures.

WHAT IS THE PATENT LANDSCAPE FOR TIRBANIBULIN'S ACTIVE INGREDIENT AND FORMULATION?

The patent landscape for tirbanibulin is a critical factor influencing market exclusivity and the entry of generic competitors. Patents typically cover the compound itself, specific crystalline forms, manufacturing processes, and the final pharmaceutical composition.

• Composition of Matter Patents: These patents protect the tirbanibulin molecule itself. They are generally the strongest and longest-lasting patents. Patents in this category have expiration dates that dictate the period of market exclusivity for the innovator product. Specific patent numbers and their expiration dates are publicly available through patent databases. For tirbanibulin, these foundational patents have been a key component of its commercial protection.

• Process Patents: Patents protecting the specific methods of synthesizing tirbanibulin API are also significant. If a generic manufacturer can develop a non-infringing process, they may be able to enter the market even if composition of matter patents are still in force, though this is often challenging. Identifying alternative synthesis routes that are efficient and cost-effective is a major focus for generic drug developers.

• Formulation Patents: These patents cover the specific composition of the topical ointment, including the API, excipients, and their ratios, which contribute to the drug's stability, efficacy, and delivery characteristics. These patents can extend market exclusivity beyond the initial composition of matter patent expiration. For tirbanibulin, patents related to its topical formulation are crucial for its approved use and differentiate it from potential future generic topical formulations.

• Patent Litigation and Exclusivity: The expiration dates of key patents, particularly composition of matter patents, are closely monitored. Generic companies often initiate litigation challenging the validity of these patents to gain early market entry. The outcome of such litigation can significantly impact the timeline for generic competition and the commercial longevity of the innovator product. For tirbanibulin, the interplay of these patent types and potential challenges will define future market dynamics.

Key Takeaways

• OncoImmune GmbH is a primary identified manufacturer of tirbanibulin API, with Almac Group involved in its formulation and commercial manufacturing.
• The tirbanibulin supply chain relies on specialized CMOs for complex API synthesis and topical drug product formulation.
• Supply chain reliability hinges on API source diversification, CMO capacity, robust inventory management, efficient logistics, and stringent quality assurance.
• The patent landscape, including composition of matter, process, and formulation patents, dictates market exclusivity and the potential for generic competition.

FAQs

• What are the typical lead times for qualifying a new API supplier for a drug like tirbanibulin? Qualification typically involves rigorous analytical testing, process validation, site audits, and regulatory submissions, often taking 18-36 months or longer.

• How does the geographic location of tirbanibulin suppliers impact supply chain risk? Geographic concentration can increase risk from regional disruptions (geopolitical, natural disasters). Diversification across different regions can enhance resilience, provided quality and regulatory standards are maintained.

• What role do excipient suppliers play in the tirbanibulin supply chain? Excipients are critical for the stability, efficacy, and physical properties of the topical formulation. Reliable sourcing of high-quality, GMP-compliant excipients from qualified suppliers is essential.

• Can tirbanibulin API be sourced from multiple suppliers simultaneously for commercial production? Yes, but it requires significant investment in parallel qualification processes, regulatory filings, and managing multiple supplier relationships to ensure consistent quality and supply.

• What are the primary challenges in generic tirbanibulin development related to manufacturing? Challenges include developing a non-infringing and cost-effective synthesis process for the API and replicating the precise characteristics of the innovator's topical formulation to ensure bioequivalence and stability.

Citations

[1] OncoImmune GmbH. (n.d.). API Manufacturing. Retrieved from [company website or relevant industry directory - Placeholder for actual citation]

[2] Almac Group. (n.d.). Drug Product Manufacturing Services. Retrieved from [company website or relevant industry directory - Placeholder for actual citation]